Quantcast
Home > Quotes > CLXT
CLXT

Calyxt, Inc. Common Stock (CLXT) Quote & Summary Data

$13.0254
*  
0.2246
1.7%
Get CLXT Alerts
*Delayed - data as of Jun. 19, 2019 10:16 ET  -  Find a broker to begin trading CLXT now
Exchange:NASDAQ
Industry: Basic Industries
Community Rating:
View:    CLXT Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 12.95 / $ 13.08
Today's High / Low
$ 13.33 / $ 12.92
Share Volume
9,994
50 Day Avg. Daily Volume
50,094
Previous Close
$ 13.25
52 Week High / Low
$ 22.32 / $ 8.83
Market Cap
425,961,046
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
9,994
50 Day Avg. Daily Volume:
50,094

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.97

Trading Range

The current last sale of $13.0254 is 47.51% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 13.33 $ 22.32
 Low: $ 12.92 $ 8.83

Company Description (as filed with the SEC)

Calyxt was incorporated in the State of Delaware in 2010 and is a majority-owned subsidiary of Cellectis, a leading gene-editing company focused on the development of immuno-oncology therapeutics. We are a healthy food ingredient company. We leverage proprietary intellectual property, our technical expertise, and an end-to-end supply chain toward our mission of "Making the Food You Love a Healthier ChoiceTM". Using our proprietary technologies and expertise, including TALEN gene-editing technology exclusively licensed to us in the field of agriculture, we develop food crops with targeted traits quickly and more cost effectively than traditional methods. Our technologies enable precise cuts to DNA in a single plant cell using the plant's natural repair machinery. This allows us to make our desired genome edit and regenerate the single cell into a full plant that includes this gene edit.  ... More ...  



Risk Grade

Where does CLXT fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 13.28
Open Date:
Jun. 19, 2019
Close Price:
$ 13.25
Close Date:
Jun. 18, 2019


Consensus Recommendation

Analyst Info